A comprehensive HCM screening should consider genes of RASopathies (Noonan, Costello, cardiofaciocutaneous syndromes), mitochondrial proteins (mitochondrial genome or nuclear genome), transcription factors, intermediate filaments (DES, FLNC, and others), calcium regulation proteins (PLN), glycogen storage diseases (Danon disease, PRKAG2, Pompe), glycoesphingolipidosis (Fabry), amyloidosis (TTR), and many others2,4,5,10–18. This evidence concerns the gene PRKAG2 and amyloidosis.